Indeed, NPM1-mutated, fit, older AML patients (≥65 years) at diagnosis have been reported to relapse and acquire resistance with negative NPM1-mutated transcripts after the application of VEN plus modified intensive chemotherapy (CAVEAT study) [72,73]. The gene discussed is NPM1; the disease is acute myeloid leukemia.